Prognostic significance of biological apoptosis factors in gastric cancer

Journal of B.U.ON.

Volumn 18, Issue 1, 2013, Pages 138-146

  Sezer, C ^a   Yildirim, Mustafa ^b   Yildiz, M ^a   Sezgin, A ^a   Donem Dilli, U ^a   Goktas, S ^a   Bulbuller, N ^a  

^a Antalya Education and Research Hospital ^*  (Turkey)

^b Antalya Education and Research Hospital   (Turkey)

Author keywords

Apoptosis; Bcl 2; Gastric cancer; p53

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR INVASION;

ADENOCARCINOMA; AGED; APOPTOSIS; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; STOMACH NEOPLASMS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84879017954     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Parkin D, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin 2005;55: 74-108. (Pubitemid 40372904)
2. McDonald J, Smalley S, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345: 725-730.
3. Bang YJ, Van Cutsem E, Feyereislova A et al. ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376: 687-697.
4. Hollstein M, Sidransky D, Vogelstein B, Harris C. P53 mutations in human cancers. Science 1991;253: 49-53. (Pubitemid 21917115)
5. Cory, S, Huang, DC, Adams, JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003; 22: 85-90.
6. Adachi Y, Mori M, Maehara Y, Suqimachi K. Dukes' classification: a valid prognostic indicator for gastric cancer. Gut 1994;35: 1368-1371. (Pubitemid 24310893)
7. Maruyama K. The most important prognostic factors for gastric cancer patients: a study using univariate and multivariate analyses. Scand J Gastroenterol 1987;22: 63-68. (Pubitemid 17112517)
8. Chau I, Morman AR, Cunningham D, Waters JS, Oates J. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer - pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 2004; 22: 2359-2403.
9. Dicken BJ, Saunders LD, Jhangri GS et al. Gastric cancer: Establishing predictors of biologic behaviour with use of population-based data. Ann Surg Oncol 2004; 11: 629-635. (Pubitemid 40486721)
10. Kerns BJ, Jordan PA, Moore MB et al. p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. J Histochem Cytochem 1992;40:1047-1051.
11. Zali MR, Moaven O, Asadzadeh Aghdaee H et al. Clinicopathological significance of E-cadherin, β-catenin and p53 expression in gastric adenocarinoma. J Res Med Sci 2009;14:239-247.
12. Kim DH. Prognostic implications of cyclin B1, p34cdc2, p27(Kip1) and p53 expression in gastric cancer. Yonsei Med J 2007;48:694-700.
13. Radovanovič D, Knezević M, Canović D, Aćimović L. Correlation between p53 expression and clinical-pathological characteristics of gastric cancer. Vojnosanit Pregl 2011;68:832-836.
14. Chen HC, Chen HJ, Khan MA et al. Genetic mutations of p53 and k-ras in gastric carcinoma patients from Hunan, China. Tumour Biol 2011;32:367-373.
15. Zhang J, He XH, Xie XY, Hu X, He C. The potential for serum p53 to predict the response to chemotherapy of patients with gastric cancer. J Int Med Res 2010;38:423-431.
16. Lim MS, Lee HW, Im H et al. Predictable factors for lymph node metastasis in early gastric cancer-analysis of single institutional experience. J Gastrointest Surg 2011;15:1783-1788.
17. Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F. p53 expression and prognosis in gastric carcinoma. Int J Cancer 1992;50:859-862.
18. Joypaul BV, Hopwood D, Newman EL et al. The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. Br J Cancer 1994;69:943-946. (Pubitemid 24140680)
19. Starzynska T, Markiewski M, Domagala W et al. The clinical significance of p53 accumulation in gastric carcinoma. Cancer 1996;77:2005-2012. (Pubitemid 26142042)
20. Maehara Y, Tomoda M, Hasuda S et al. Prognostic value of p53 protein expression for patients with gastric cancer - a multivariate analysis. Br J Cancer 1999;79:1255-1261. (Pubitemid 29087907)
21. Tzanakis NE, Peros G, Karakitsos P et al. Prognostic significance of p53 and Ki67 proteins expression in Greek gastric cancer patients. Acta Chir Belg 2009;109:606-611.
22. Lazǎr D, Tǎban S, Sporea I et al. The immunohistochemical expression of the p53-protein in gastric carcinomas. Correlation with clinicopathological factors and survival of patients. Rom J Morphol Embryol 2010;51:249-257.
23. Motojima K, Furui J, Kohara N, Ito T, Kanematsu T. Expression of p53 protein in gastric carcinomas is not independently prognostic. Surgery 1994;116:890-895. (Pubitemid 24347199)
24. Gabbert HE, Muller W, Schneiders A, Meier S, Hommel G. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer 1995;76: 720-726.
25. Joo YE, Chung IJ, Park YK et al. Expression of cyclooxygenase-2, p53 and Ki-67 in gastric cancer. J Korean Med Sci 2006;21:871-876.
26. Juvan R, Hudler P, Gazvoda B, Repse S, Bracko M, Komel R. Significance of genetic abnormalities of p53 protein in Slovenian patients with gastric carcinoma. Croat Med J 2007;48:207-217. (Pubitemid 46651027)
27. Deveci MS, Deveci G. Prognostic value of p53 protein and MK-1 (a tumor-associated antigen) expression in gastric carcinoma. Gastric Cancer 2007;10:112-116. (Pubitemid 46955939)
28. Lee DY, Park CS, Kim HS, Kim JY, Kim YC, Lee S. Maspin and p53 protein expression in gastric adenocarcinoma and its clinical applications. Appl Immunohistochem Mol Morphol 2008;16:13-18.
29. Azarhoush R, Keshtkar AA, Amiriani T, Kazemi-Nejad V. Relationship between p53 expression and gastric cancers in cardia and antrum. Arch Iran Med 2008;11:502-506.
30. Ismail HM, Moneer M, El-Baradie M, Khorshid O, Touny A. Clinicopathologic and prognostic significance of overexpression of her-2/neu and p53 oncoproteins in gastric carcinoma using tissue microarray. J Egypt Natl Canc Inst 2007;19:147-157.
31. Manne U, Myers RB, Moron C et al. Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int J Cancer 1997;74:346-358. (Pubitemid 27321807)
32. Sahan E, Tetikkurt US, Balci C, Igdem AA, Gultekin SE, Erdogan N. Evaluation of P53 and Bcl-2 expression with Ki-67 proliferation index in prostatic aciner adenocarcinoma; Their correlation with histopathological and clinical prognostic factors. Turkish J Urol 2003; 29: 250-257. (Pubitemid 37203291)
33. Müller W, Schneiders A, Hommel G, Gabbert HE. Prognostic value of bcl-2 expression in gastric cancer. Anticancer Res 1998;18:4699-4704. (Pubitemid 29042046)
34. Tsamandas AC, Kardamakis D, Tsiamalos P et al. The potential role of Bcl-2 expression, apoptosis and cell proliferation (Ki-67 expression) in cases of gastric carcinoma and correlation with classic prognostic factors and patient outcome. Anticancer Res 2009;29:703-709.
35. Yildirim M, Suren D, Goktas S et al. The predictive role of Bcl-2 expression in operable, locally advanced or metastatic gastric carcinoma. J BUON 2012; 17: 106-109.
36. Zafirellis K, Karameris A, Milingos N, Androulakis G. Molecular markers in gastric cancer: can p53 and bcl-2 protein expressions be used as prognostic factors? Anticancer Res 2005;25:3629-3636. (Pubitemid 41105253)
37. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 1994;54:2095-2097. (Pubitemid 24138678)
38. Saegusa M, Takano Y, Okayasu I. Bcl-2 expression and its association with cell kinetics in human gastric carcinomas and intestinal metaplasia. J Cancer Res Clin Oncol 1995;121:357-363.
39. Smith L, Berrieman HK, O'Kane SL, Campbell A, Maraveyas A, Cawkwell L. Immunohistochemical detection of apoptotic markers in gastric cancer. Oncol Res 2006;15:441-444.
40. Aizawa K, Ueki K, Suzuki S et al. Apoptosis and bcl-2 expression in gastric carcinomas: correlation with clinicopathological variables, p53 expression, cell proliferation and prognosis. Int J Oncol 1999;14:85-91.
41. Inada T, Kikuyama S, Ichikawa A, Igarashi S, Ogata Y. Bcl-2 expression as a prognostic factor of survival of gastric carcinoma. Anticancer Res 1998;18:2003-2010. (Pubitemid 28344862)
42. Triantafyllou K, Kitsanta P, Karamanolis DG, Kittas C, Ladas SD. Epithelial cell turnover, p53 and bcl-2 protein expression during oncogenesis of early and advanced gastric cancer in a Western population. Dig Liver Dis 2008;40:39-45. (Pubitemid 50008438)
43. Wiksten JP, Lundin J, Nordling S, Kokkola A, Haglund C. Comparison of the prognostic value of a panel of tissue tumor markers and established clinicopathological factors in patients with gastric cancer. Anticancer Res 2008;28:2279-2287.
44. Lee HK, Lee HS, Yang HK et al. Prognostic significance of Bcl-2 and p53 expression in gastric cancer. Int J Colorectal Dis 2003;18:518-525. (Pubitemid 37265866)
45. Liu X, Cai H, Huang H, Long Z, Shi Y, Wang Y. The prognostic significance of apoptosis-related biological markers in Chinese gastric cancer patients. PLoS One 2011;6:e29670.
46. Qiao L, Wong BC. Targeting apoptosis as an approach for gastro-intestinal cancer therapy. Drug Resist Updat 2009;12:55-64.